[1]王 军,魏 洁△,江海峰,等.Ⅲ期老年胸段食管癌术后放疗与同步放化疗临床疗效对比研究*[J].陕西医学杂志,2018,(12):1568-1571,1575.
　Wang Jun,Wei Jie,Jiang Haifeng,et al.Clinical comparison between postoperative radiotherapy and concurrent chemoradiotherapy for with stage III esophageal squamous cell carcinoma in the elderly patients[J].,2018,(12):1568-1571,1575.
点击复制

Ⅲ期老年胸段食管癌术后放疗与同步放化疗临床疗效对比研究*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2018年12期
页码:
1568-1571,1575
栏目:
临床研究
出版日期:
2018-12-31

文章信息/Info

Title:
Clinical comparison between postoperative radiotherapy and concurrent chemoradiotherapy for with stage III esophageal squamous cell carcinoma in the elderly patients
文章编号:
DOI:10.3969/j.issn.1000-7377.2018.12.016
作者:
王 军1; 魏 洁1△; 江海峰2; 项 飞1; 杜兴龙1; 吕星旺1; 包宗玲1; 丁仁平1
1.安徽医科大学滁州临床学院（安徽省滁州市第一人民医院）放疗科（滁州 239000）, 2.安徽医科大学滁州临床学院（安徽省滁州市第一人民医院）心胸外科（滁州 239000）
Author(s):
Wang Jun;  Wei Jie;  Jiang Haifeng; et al.
Department of Oncology, Affiliated Chuzhou Clinical College of Anhui Medical University(Chuzhou 239000)
关键词:
食管肿瘤 放射疗法 化学疗法; 辅助 生活质量 老年人
Keywords:
Key words Esophageal neoplasms Radiotherapy Chemotherapy adjuvant Quality of life Aged
分类号:
R735.1
文献标志码:
A
摘要:
摘 要 目的:比较术后放疗组与同步放化疗组的不良反应发生率、生活质量影响及生存预后。方法:收集Ⅲ期食管癌患者67例，其中术后放疗组33例，同步放化疗34例。根据美国肿瘤放射治疗协会（RTOG）标准和国立癌症研究所毒性判定标准（CTCAE 4.0版）评价治疗期间急性不良反应。随访两组患者治疗结束后6月生活质量及1年、2年和3年生存时间。结果：两组患者在呕吐、食欲不振、食管炎、血液毒性等方面的不良反应发生率均较高。同步放化疗组在呕吐、血液毒性反应明显高于术后放疗组（P＜0.05），其他不良反应两组相似（均P>0.05）。在QLQ-C30量表中，同步放化疗组患者的总健康状况、躯体功能、疼痛及经济困难状况4项指标优于术后放疗组（P＜0.05），在QLQ-OES18量表中，同步放化疗组患者的反流、咳嗽、吞咽呛咳及言语4项指标优于术后放疗组（P＜0.05）。术后放疗组和同步放化疗组的1年、2年及3年生存率分别为80.0％、50.0％和30.0%％及75.7％、51.5%和21.2％，两组间比较无统计学意义（P＞0.05）。结论：对局部晚期老年食管癌患者而言，术后放疗与同步放化疗均可以作为其治疗的有效手段，且同步放化疗组的生活质量明显优于术后放疗组。
Abstract:
Abstract 〖JP2〗Objective: To compare clinical adverse reactions, quality of life and long-term overall survival(OS) between postoperative radiotherapy group and chemoradiotherapy group in the treatment of advanced esophageal neoplasms. Methods: 67 patients with stage III esophageal neoplasms were selected for retrospective analysis. Depending on the treatment, of the 67 cases, 33 cases underwent postoperative radiotherapy. 34 patients were treated with 3DRT combined chemotherapy(chemoradiotherapy group). Evaluation of acute adverse reactions during treatment. Quality of life in June, following up with two groups of patients. The 1, 3 and 5-year overall survival rates of patients. Results: The incidence of adverse reactions in vomiting, loss of appetite, radioactive esophagitis and hematotoxicity were higher in both groups. The incidence rates of nausea and vomiting, appetite degression, leucopenia, radiaton-induced esophagitis were significantly higher in both groups. The toxicity of vomiting and blood in the synchrotron chemotherapy group was significantly higher than that in the postoperative radiotherapy group（P＜0.05）.In QLQ-C30, the total health, body function, pain and financial difficulties of patients with synchronous chemotherapy were better than those of postoperative radiotherapy（P＜0.05）.In QLQ-OES18, the reflux, cough, swallowing cough and speech of patients with synchrotron chemotherapy were better than those of postoperative radiotherapy（P＜0.05）.The 1, 2 and 3years of os were 80.0%, 50.0% , 30.0 % and 75.7%, 51.5 % , 21.2 % among postoperative radiotherapy(PORT) and postoperative chemoradiotherapy(POCRT). There was no statistically significant comparison between the two groups（P＞0.05）.Conclusion: For locally advanced elderly patients with esophageal neoplasms, all patients can tolerate adverse reactions after symptomatic treatment and do not affect the process. Postoperative radiotherapy and simultaneous chemotherapy can be used as effective treatment for stage Ⅲ esophageal neoplasms. The quality of life of the synchrotron chemotherapy group was superior to that of the postopera tiveradiotherapy group.〖LM〗

参考文献/References:


[1] Reeh M, Nentwich MF, Asani S, et al. Locally advanced esophageal carcinoma: is there still a role of surgery alone without neoadjuvant treatment? [J]. J Gastrointest Surg, 2015, 19 (4): 587-593.
[2] 张安度, 韩 晶, 韩 春, 等. 1257例食管鳞癌三维放疗+化疗的临床研究[J]. 中华放射肿瘤杂志，2017，26(5): 517-521.
[3] Zhu HT, Ai DS, Tang HR, et al. Long-Term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma[J]. World J Gastroenterol, 2017, 23(3): 540-546.
[4] Marlene M, Rosemarie K, Bodil I, et al. Quality of life measurements as an indicator for timing of support after oesophagectomy for cancer:a prospective study[J]. BMC Health Services Research, 2015, 12（15）：96-103.
[5] 陈万青, 李 贺, 孙可欣, 等. 2014年中国恶性肿瘤发病和死亡分析[J]. 中华肿瘤杂志, 2018, 40(1): 5-13.
[6] 王 铮,董新伟,银 瑞. 不同手术方式治疗食管癌的疗效分析[J]. 重庆医学, 2018, 47（16）： 2181-2184，2188.
[7] 刘 君. 影响食管切除术后颈部吻合口良性狭窄的相关因素分析[J]. 陕西医学杂志, 2015, 44(12): 1667-1668.
[8] 沈文斌, 高红梅, 祝淑钗, 等. T1-4N0-1M0期胸段食管鳞癌根治性切除术后失败模式对术后辅助治疗的意义[J]. 中华放射医学与防护杂志, 2018, 38(4): 265-272.
[9] 王修身, 张羲茜, 刘 晓, 等. 食管癌同步放化疗的疗效及预后因素分析[J]. 中华放射肿瘤杂志, 2017, 26(4): 400-404.〖ZK)〗
[10] 马海龙, 张 勇, 邱春丽, 等. 中国西北地区食管癌患者照顾者生存质量及影响因素分析[J]. 陕西医学杂志, 2016, 45(2): 245-247.
[11] 任雪姣, 王 澜, 韩 春, 等. 食管癌同期放化疗不同放疗剂量远期疗效分析[J]. 中华放射肿瘤杂志, 2017, 26(9): 1006-1011.
[12] 贝宴屏，严丹方，严森祥. 老年食管鳞癌淋巴结累及野放射治疗的回顾性资料分析[J]. 中华放射医学与防护杂志，2015，35(7)，510-513, 558.
[13] 罗毅君, 王晓莉, 于金明. 食管鳞癌累及野放疗的理论和实践[J]. 中华放射肿瘤杂志, 2017, 26(8): 965-969.
[14] Yeh HL, Hsu CP, Lin JC, et al. A retrospective study of postoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma[J]. Form J Surg, 2012, 45: 172-177.
[15] Liu J, Xue L, Zhen F, et al. Efficacy and safety of chemoradiation therapy compared with chemotherapy for esophageal carcinoma: An updated meta-analysis of randomized controlled trials[J]. Medicine, 2017, 96(47): 8929-8937.
[16] Van Hagen P, Hulshof MC, Van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med, 2012, 366(22): 2074-2084.
[17] Mariette C, Dahan L, Mornex F, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage Ⅰ andⅡ esophageal cancer: final analysis of randomized controlled phase Ⅲ trial FFCD 9901[J]. J Clin Oncol, 2014, 32(23): 2416-2422.
[18] 左婷婷, 郑荣寿, 曾红梅, 等. 中国食管癌发病状况与趋势分析[J]. 中华肿瘤杂志, 2016, 38（9）: 703-708.
[19] 贺宇彤, 李道娟, 梁 迪, 等. 2013年中国食管癌发病和死亡估计[J]. 中华肿瘤杂志, 2017, 39(4): 315-320.

备注/Memo

备注/Memo:
*安徽省卫生和计划生育委员会科研计划项目(2016-QK008)
更新日期/Last Update: 2019-01-21